Manufacturing Quality Issues Sideline BI and Lilly’s Diabetes Candidate

The FDA has rejected a diabetes drug co-developed by Boehringer Ingelheim and Eli Lilly due to unresolved quality issues at one of Boehringer’s plants. The complete response letter the agency issued for the pharma partners’ NDA for empagliflozin demanded resolution of the quality issues before approval can be given.
Drug Industry Daily